FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness

The FDA has mandated that manufacturers of GLP-1 weight-loss and diabetes drugs add warning labels regarding a rare eye condition linked to sudden vision loss. While a causal link is not yet proven, studies suggest an increased risk for patients using these medications.
Why it matters
This regulatory action impacts millions of patients using popular drugs like Ozempic and Wegovy, highlighting the importance of ongoing safety monitoring for widely prescribed pharmaceuticals.
The Food and Drug Administration said Monday that GLP-1 drugmakers must add a warning label about a rare eye condition that can cause sudden blindness. The condition, called nonarteritic anterior ischemic optic neuropathy, or NAION, affects the optic nerve, which carries signals from the eye to the brain. When blood flow to the nerve is reduced or blocked, it can cause sudden vision loss. The condition is permanent with no known treatment. The FDA said “there is a potential increased risk of rare NAION” in people taking GLP-1 drugs. The agency’s requirement applies to all GLP-1s, including Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro and Zepbound, as well as several older GLP-1 diabetes medications. Spokespeople for both Novo Nordisk and Eli Lilly said patient safety is their top priority.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in